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Reduced toxicant prototype (RTP) cigarettes with substantially reduced levels of tobacco smoke toxicants
have been developed. Evaluation of these prototype cigarettes included measurement of biomarkers of
exposure (BoE) to toxicants in smokers switched from conventional cigarettes to the RTPs. A 6-week sin-
gle-blinded randomised controlled study with occasional clinical conﬁnement was conducted (Trial reg-
istration: ISRCTN7215735). All smoking subjects smoked a conventional cigarette for 2-weeks. Control
groups continued to smoke the conventional cigarette while test groups switched to one of three RTP
designs. Clinical conﬁnement and additional assessments were performed for all smoking groups after
2 and 4-weeks. A non-smoker group provided background levels of BoE. On average, smokers switched
to RTPs with reduced machine yields of toxicants had reduced levels of corresponding BoEs. For vapour
phase toxicants such as acrolein and 1,3-butadiene reductions of P70% were observed both in smoke
chemistry and BoEs. Reductions in particulate phase toxicants such as tobacco-speciﬁc nitrosamines, aro-
matic amines and polyaromatic hydrocarbons depended upon the technologies used, but were in some
cases P80% although some increases in other particulate phase toxicants were observed. However,
reductions in BoEs demonstrate that it is possible to produce prototype cigarettes that reduce exposure
to toxicants in short-term use.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Background
Many epidemiological studies of tobacco smoking ﬁnd that risks
to health are dose related and increase particularly with duration
of smoking but also with level of daily consumption (International
Agency for Research on Cancer, 2007; Doll et al., 1994). Cessation
generally leads to reductions in health risks, but the extent and
speed of any reduction varies by disease (International Agency
for Research on Cancer, 2007; Doll et al., 1994). The risks can be as-
sumed to result from repeated and prolonged exposure to a range
of tobacco smoke toxicants, which leads to a gross insult to thecigarettes per day; FDA, Food
sure; RTP, reduced-toxicant
bacco-speciﬁc nitrosamines;
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pperd), Alison_eldridge@bat.
dam), christopher_proctor@
(I. Meyer).
C-ND license. respiratory and cardiovascular systems (e.g. through mechanisms
of inﬂammation or oxidative stress), or to exposure to individual
or classes of toxicants that exert toxic effects through more speciﬁc
mechanisms (Institute of Medicine, 2001). Whilst, there is a level of
understanding of how exposure to a particular tobacco smoke con-
stituent relates to etiology disease (Fowles and Dybing, 2003;
Rodgman and Green, 2003; Cunningham et al., 2011) there remains
uncertainty about which smoke constituent reductions might re-
sult in reductions in smoking-related diseases.
Reducing the health impact of tobacco use is a clear public
health priority and has led to a series of regulatory and educational
initiatives to persuade people not to smoke (World Health Organi-
sation, 2011). Despite these efforts, smoking rates in the adult pop-
ulation in many countries remain at between 15% and 25%.
Although they are declining slowly in many countries (World
Health Organisation, 2011), the World Health Organisation
(WHO) has forecast that there will be around 1.5 billion tobacco
smokers worldwide in 2050 (World Health Organisation, 2002).
Both current scientiﬁc study and public policy debate are consider-
ing whether public health gains, related to individual risks and
population risks, could arise from reducing toxicant exposure in
people who continue to use tobacco.
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a US Institute of Medicine report published in 2001which sought to
evaluate whether a scientiﬁc basis for tobacco harm reduction,
including the development and evaluation of what was termed po-
tential reduced-exposure products (PREPs) was feasible (Institute
of Medicine, 2001). PREPs were deﬁned as products that substan-
tially reduce exposure to one or more tobacco smoke toxicants
and as a result could be reasonably expected to reduce the risk of
one or more speciﬁc diseases or other adverse health effects.
Tobacco smoke is a complex mixture of many thousands of indi-
vidual substances, approximately 150 ofwhich have been identiﬁed
as toxicants (Fowles and Dybing, 2003). Various toxicological ap-
proaches have been applied to try to identify which toxicants are
themost important to the various diseases causedby smoking (Fow-
les andDybing, 2003; RodgmanandGreen, 2003; Cunninghamet al.,
2011).Wehave for some years been developing and characterising a
series of technologies that have potential to reduce some of these
toxicants in tobacco and tobacco smoke (McAdam et al., 2011a;
Liu and Porter, 2011; Branton et al., 2011a, b). In this studywe com-
bined some of these technologies to produce a series of reduced tox-
icant prototype (RTP) cigarettes that when assessed in the
laboratory, using smokingmachines, resulted in reductions in yields
of a range of tobacco smoke toxicants, as compared to both scientiﬁc
and commercial controls (McAdam et al., 2011b). The scientiﬁc con-
trols were test products containing single technologies, whilst the
commercial controls were cigarettes matched for ISO tar and nico-
tine yield, available on the German market at the time of the study.
It is well known that the yield of toxicants produced when a cig-
arette is smoked using a smoking machine will depend on the way
in which the machine is set up to smoke the cigarette, and is par-
ticularly dependent on the size and the frequency of the puffs. Lar-
ger and more frequent puffs mean more tobacco is burnt in the
creation of the mainstream smoke and hence the levels of the tox-
icants produced are increased. This is important because it is also
well known that human smoking behaviour (including the number
and size of puffs taken) varies widely, both from occasion to occa-
sion for a particular smoker and between smokers. Therefore, lab-
oratory machine yields will not necessarily reﬂect toxicant
exposure in an individual smoker or a population of smokers. Even
so, several studies have correlated levels of biomarkers of exposure
(BoE), such as toxicant metabolites, with levels of toxicants in the
smoke collected on smoking machines. For example, Ashley re-
ported lower levels of BoE associated with tobacco speciﬁc nitros-
amines (TSNA) in groups of smokers using cigarettes with low
TSNA tobacco blends (Ashley et al., 2010). In another study, Sarkar
reported reductions in BoE associated with several volatile tobacco
smoke toxicants in subjects switched from conventional cigarettes
to cigarettes with activated carbon (an adsorbent of volatile com-
pounds) added to the ﬁlter (Sarkar et al., 2008).
Three RTPs (Table 1), each with different relative levels of toxi-
cant yields, have been used in this study to test the hypothesis that
the reduced yields of some toxicants in mainstream smoke would
lead to reduced levels of corresponding BoE in smokers, thereby
indicating a reduction in smoke toxicant exposure.
The smoke toxicants followed in this study were determined by
the availability of established BoE methods, therefore it was not
possible to follow all of the smoke toxicant reductions associated
with these RTPs (McAdam et al., 2011b). The BoE and associated
smoke toxicants assessed in this study can be found in Table 4.
The primary objective of the study was to estimate and compare
cigarette smoke exposure in healthy adult smokers by assessment
of BoE and mouth level exposure (MLE) to tar and nicotine as mea-
sured by ﬁlter analysis, and to quantify any changes in exposure
after switching from control cigarettes to RTPs.
Secondary objectives of the study were to determine changes in
a variety of measures during consumption of RTP cigarettes andreference cigarettes using sensory testing questionnaire, assess-
ments of smoking behaviour, including pufﬁng and inhalation
behaviour, a quality of life (QoL) questionnaire, and basic physio-
logical measures.
This paper focuses on the primary objective of the study.2. Materials and methods
A six week, single-centre, single-blinded, controlled, forced
switch clinical study was conducted at Momentum Pharma Ser-
vices, Hamburg, Germany. The study was designed and conducted
in accordance with the ethical principles of the Declaration of Hel-
sinki and the International Committee on Harmonisation for Good
Clinical Practice. The protocol was approved by the ethics commit-
tee of the Artzekammer Hamburg and the study conducted be-
tween December 2008 and June 2009. All subjects provided
written informed consent. The study is registered with Current
Controlled Trials, number ISRCTN72157355.
2.1. Subjects
Subjects were recruited into the study using a combination of
the clinic’s own website and local advertising that did not refer
to the characteristics of the study products. Eligible subjects were
healthy adult (>21 years) smokers and non-smokers of either sex
and any ethnic origin who lived in or around Hamburg, Germany.
Eligibility was assessed by the principal investigator on the basis of
the following criteria.
Inclusion criteria for smokers required subjects: to be regular
smokers of either 6–7 mg or 1–2 mg ISO tar yield cigarettes; to
have typically self-reported cigarette consumption of between 6
and 30 cigarettes per day; to have been a smoker for >3 years; to
have smoked their current brand for >6 months (where the current
brand was typical of the German market in terms of format (‘‘king
size’’), blend style (American blended, non-mentholated) and ﬁlter
type (plain cellulose acetate)); and to be willing to switch to a no-
vel product. Eligible non-smokers were required to have not
smoked for >5 years and have a urine cotinine level of <10 ng/mL.
Universal exclusion criteria were as follows: a clinically rele-
vant health condition or abnormal ﬁndings on physical examina-
tion; participation in a clinical trial within 90 days of day 1;
donation or loss of P400 mL blood in the past 90 days; acute ill-
ness requiring treatment within the previous 4 weeks; use of nic-
otine or tobacco products other than ﬁltered cigarettes; any
history of drug or alcohol abuse; use of bronchodilators within
the previous 12 months; use of systemic medication (except hor-
monal contraception or hormone-replacement therapy) within
the previous 14 days; employment in the tobacco, journalism, pub-
lic relations, market research or advertising industries; a positive
urine pregnancy test, use of non-reliable contraceptive methods
or lactation in women of childbearing age. Smokers were excluded
if they self-reported or were observed to be non-inhalers.
All subjects were screened for study entry by physical examina-
tion, electrocardiography, clinical laboratory tests, lung function
tests, medical history, urinary cotinine test (non-smokers), the
ability to understand the study protocol and give written informed
consent to participate and a willingness to refrain from consuming
products containing caffeine for 24 h and alcohol for 72 h before
the ﬁrst day of each conﬁnement visit.
2.2. Products
Five products were manufactured for this study (Table 1). Fur-
ther details of the designs and associated smoke chemistries of
all ﬁve products have been published previously (McAdam et al.,
Table 1
Construction characteristics and smoke yields* for control and reduced-toxicant prototype cigarettes used in the study.
CC1 TSS1 BT1 CC6 TSS6
Tobacco blend composition US style 80% US style/20% TSS 75.4% washed, extracted and enzyme treated
tobacco/20.3% Virginia tobacco/4.3% oriental
tobacco
US style 80% US style/20% TSS
Cigarette rod length (mm) 57 57 57 57 57
Blend weight (mg) 570 572 654 605 622
Cigarette paper 50 CU
standard
50 CU standard 50 CU standard 50 CU
standard
50 CU standard
27 mm ﬁlter type Single-stage Three-stage Three-stage Single-stage Two-stage
Ventilation (%) 78 81 79 52 46
Pressure drop (mmWG) 86 97 91 85 109
Mouth-end stage 27 mm CA 7 mm CA 7 mm CA 27 mm CA 15 mm CA
Middle stage 10 mm CA with 20 mg
CR20L
10 mm CA with 20 mg CR20L
Tobacco end stage 10 mm CA with 60 mg C 10 mm CA with 60 mg C 12 mm CA with
80 mg C
Target ISO Tar yield (mg) 1 1 1 6 6
NFDPM (mg/cig) 18.9 17.3 17.8 24.4 20.7
Nicotine (mg/cig) 1.3 1.2 1.5 1.6 1.4
Nitrosamines (ng/cig)
NAB (RL = 0.1 ng/cig) 13.6 6.6 1.4 12.1 7.6
NAT (RL = 0.2 ng/cig) 124.5 70.3 19.1 117.6 69.5
NNK (RL = 0.2 ng/cig) 57.9 48.2 10.1 80.0 44.5
NNN (RL = 0.2 ng/cig) 245.2 76.0 10.2 146.9 72.8
Aromatic amines (ng/cig)
2-Aminonaphthalene
(RL = 0.5 ng/cig)
13.1 11.5 7.4 14.6 14.8
3-Aminobiphenyl (RL = 0.1 ng/
cig)
3.5 3.0 1.8 4.1 3.3
4-Aminobiphenyl (RL = 0.1 ng/
cig)
2.8 2.5 1.2 3.1 2.7
o-Toluidine (RL = 2.3 ng/cig) 68.1 60.1 50.6 88.1 76.2
Carbonyls (lg/cig)
Acrolein (RL = 1.0 lg/cig) 130.5 52.5 75.0 139.4 62.3
Crotonaldehyde (RL = 1.1 lg/cig) 41.6 6.0 10.9 45.2 7.0
Hydrocarbons and PAH (lg/cig)
1,3-Butadiene (RL = 7.0 lg/cig) 39.6 27.2 53.4 63.6 36.8
Naphthalene (RL = 62.5 lg/cig) 2182.5 643.8 484.9 2952.3 565.6
Fluorene (RL = 62.5 lg/cig) 230.5 148.3 247.3 315.7 240.9
Phenanthrene (RL = 62.5 lg/cig) 524.4 191.4 541.5 739.8 589.7
Pyrene (RL = 9.4 lg/cig) 70.4 64.6 75.3 108.1 80.3
Abbreviations: TSS = tobacco substitute sheet; BT = blend treatment; CA = cellulose acetate ﬁlter material; CR20L = amine-functionalised resin ﬁlter additive; C = high-activity
polymer-derived carbon; CU = CORESTA unit (volume air [cm3] passing through 1 cm2 paper min1 at constant pressure difference of 1.0 kPa). NNAL = 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanol; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N-nitrosonornicotine, NAB = N-nitrosoanabasine; NAT = N-nitrosoanata-
bine; 3-HPMA = 3-hydroxypropylmercapturic acid; PAH = polynuclear aromatic hydrocarbons. RL = reporting limit.
* Measured under the Health Canada Intense smoking regime [10].
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chine smoking, relevant to the current study are summarised in Ta-
ble 1. Testing cigarettes under ISO smoking conditions, we found
that some of the toxicant levels were below reporting limits (RL)
(Table 1), and so we report in this paper smoke toxicant yields ac-
quired after machine smoking under Health Canada Intense smok-
ing conditions which produces higher yields. Cigarettes used in this
clinical study were sourced from the same manufacturing batch as
those from which the previously published data were obtained.
Two of the ﬁve products were manufactured as controls for this
study, one with a 6 mg ISO tar yield (CC6) and one with a 1 mg ISO
tar yield (CC1). These products were based on British American To-
bacco cigarettes on sale in Germany at the time of the study and
were similar to the market leading products in terms of format
(‘‘king sized’’), tobacco blend style (American blended) and ﬁlter
type (cellulose acetate).
The other three products were reduced toxicant prototype (RTP)
cigarettes (Table 1). The RTPs used different combinations of four
novel toxicant reducing technologies.
Two novel technologies were included in the tobacco blend of
the prototype cigarettes with the aim of reducing levels of toxicant
yields: a tobacco substitute sheet (TSS), the use of which results ina reduced amount of tobacco being burnt and the smoke being di-
luted by a proportion of the glycerol contained in the sheet (McAd-
am et al., 2011a), and a tobacco blend treatment (BT) that lowers
levels of proteins and polyphenols in tobacco, resulting in reduced
levels of aromatic amines, hydrogen cyanide and phenolic com-
pounds in smoke (Liu and Porter, 2011).
In order to reduce levels of some vapour phase toxicants, two
different adsorbents were used in the ﬁlters of the RTP cigarettes:
a high performance carbon that had signiﬁcantly better adsorption
capacity than carbons typically used in the manufacture of some
conventional cigarettes (Branton et al., 2011a) and an amine-func-
tionalised resin with chemisorptive properties for carbonyls and
volatile acids (Branton et al., 2011b).
Combinations of these technologies were used to develop two
prototype cigarettes with target ISO tar yield of 1 mg, and one with
a target ISO tar yield of 6 mg. The 1 mg ISO tar yield was chosen as
it is the lowest yield category under the ISO smoking regime in
Germany. The ﬁrst of these 1 mg prototypes (TSS1) incorporated
tobacco substitute sheet into the tobacco blend, and a three stage
ﬁlter containing both the high performance carbon and amine
functionalised resin in addition to cellulose acetate (the material
typically used for cigarette ﬁlters). The second, (BT1) incorporated
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TSS1 (see Table 1).
Cigarettes of around 6 mg ISO tar yield were considerably more
popular in Germany in 2007–8 than 1 mg ISO tar cigarettes, and so
a further prototype was developed at this higher ISO tar yield. This
prototype (TSS6) also included the tobacco substitute sheet in the
blend but used a two stage ﬁlter containing only the high perfor-
mance carbon in addition to the traditional cellulose acetate.
2.3. Study groups
Subjects who smoked 6–7 mg ISO tar yield cigarettes were as-
signed to the 6 mg control group, which smoked CC6 throughout
the study (group 1), or to the 6 mg RTP group, which switched from
CC6 to TSS6 (group 2). The subjects who smoked 1–2 mg ISO tar
yield cigarettes were assigned either to the 1 mg control group,
which smoked CC1 throughout the study (group 3), or to one of
two 1 mg RTP groups, which switched from CC1 to either the
TSS1 RTP (group 4) or the BT1 RTP (group 5). Group 6 comprised
the non-smoking control group (Fig. 1). Group assignment was
not based on formal randomisation, but participants were assigned
to subgroups within the ISO tar yields (i.e. control or test group) to
ensure age and sex were matched as closely as possible (see Ta-
ble 2). Smoking participants were unaware of group allocation
throughout the study.
2.4. Study protocol
The study was mainly ambulatory, but included short periods of
clinical conﬁnement when samples were collected for analysis
(Fig. 1). On days 1, 7, 21 and 35, smokers made ambulatory visits
to the clinic to collect supplies of cigarettes. For each ambulatory
period, individuals were supplied with a number of cigarettes
equal to their self-reported daily consumption plus two further
packs; when consumption values were recorded, subjects did not
know that supplies would be based on these values. All cigarettes
were supplied unbranded and in plain white packs bearing health
warnings and a four-digit alphanumerical code referencing the
product, which also appeared on each cigarette. To assess compli-
ance during ambulatory periods, subjects completed daily diaries
of cigarette consumption. They were also required to collect the
butts of smoked cigarettes each day and return them along with
any unsmoked cigarettes. Although subjects were asked to smoke
only supplied cigarettes for the duration of the study, an ‘‘honesty’’
policy was used to enable them to record any other cigarettes
smoked without risk of expulsion from the study. During these
ambulatory periods, no restrictions were placed on when and
how many cigarettes were smoked and no samples were taken
for analysis. On day 1, subjects were advised to refrain from grilled,
smoked, fried or barbecued food and cruciferous vegetables duringSmokers
= Ambulatory Visit
Baseline
control product R
WEEK 1 WEEK 2 WEEK 3
Control Groups 
1 & 3
Test Groups 
2, 4 & 5 
non
smokers Group 6
= 2, 3 & 4 Day Resid
Day 1 Day 14
Baseline
Control product
Fig. 1. Study design. Key: Blue shading – Control Groups, Grnon-residential parts of the study, and were instructed to docu-
ment the consumption of such foods in a diary.
On days 1–14, all smokers received CC6 or CC1 control ciga-
rettes according to group allocation. On the evening of day 12,
smokers entered the clinic for the ﬁrst period of clinical conﬁne-
ment, during which cigarettes were issued singly on request after
the ﬁlter of the previous smoked cigarette had been returned. This
approach ensured complete collection of ﬁlters and accurate ciga-
rette consumption data. On the evening of day 14, group 2 was
switched from CC6 to TSS6, group 4 from CC1 to TSS1 and group
5 from CC1 to BT1. Groups 1 and 3 continued to smoke CC6 and
CC1 respectively. All smokers continued to smoke these supplied
cigarettes for the remaining 4 weeks of the study.
On the evening of day 15 all smoking subjects left the clinic
with sufﬁcient cigarettes to last until their next ambulatory visit
on day 21. Further clinical conﬁnement periods took place for these
groups on days 26–28 and 38–42.
Non-smokers completed two periods of clinical conﬁnement
that bracketed, in time, the smoking groups (days 5–6 and 54–56
of the study). At no point were non-smokers in clinic at the same
time as smokers and indeed each smoking group (1–5) occupied
the clinic at different times, ensuring no mixed groups of control
and test, or 6 mg and 1 mg ISO tar yield.
For all subjects, to minimise potential dietary interferences on
BoE levels, restrictions were placed on caffeine and alcohol intake
for 24 h and 72 h respectively before the start and to the end of the
conﬁnement periods, and subjects received a standardised bulk
diet (excluding grilled, smoked, fried and barbequed foods) during
stays at the clinic.
During all conﬁnement visits, 24 h urine samples were taken for
BoE analysis from all subjects. Although clinical conﬁnement virtu-
ally ensured complete 24 h urine sample collection, completeness
was conﬁrmed using consistency of creatinine clearance values,
calculated from serum and urine creatinine measures taken at each
24hr period. Twenty-one urinary BoE were measured for tobacco
smoke toxicants for which validated methods were available (Ta-
bles 4 and 5). The methods utilised for BoE for tobacco-speciﬁc
nitrosamines, aromatic amines, crotonaldehyde and polyaromatic
hydrocarbons (PAHs) have been reported elsewhere (Kavvadias
et al., 2009; Riedel et al., 2006; Scherer et al., 2007; Ramsauer
et al., 2011) and the methods utilised for BoE of nicotine and
metabolites, acrolein and 1,3-butadiene were adapted from pub-
lished methods (Sarkar et al., 2008; Feng et al., 2007; Sheldon,
2003). Levels were reported as the quantity of BoE excreted over
24 h, and were calculated as the product of urine BoE concentra-
tion and the volume of urine. Saliva samples were collected and
analysed as previously described (Shepperd et al., 2009), to mea-
sure salivary cotinine as a check on compliance with the protocol.
Urinary BoE results for day 14 for smokers were treated as baseline
values, results for days 28 and 41 were treated as mid-point andemain on control product
WEEK 4 WEEK 5 WEEK 6
Switch to RTP
n=50
ential Visit 
n=50
n=50
Day 28 Day 41
een shading – Test Groups, No Shading – non-smokers.
Table 2
Characteristics of participants by study group.
Group 1
(CC6; n = 50)
Group 2
(TSS6; n = 50)
Group 3
(CC1; n = 51)
Group 4
(TSS1; n = 50)
Group 5
(BT1; n = 50)
Group 6
(non-smokers; n = 50)
Enrolled (n) 50 50 51 50 50 50
Completed (n) 49 49 45 47 47 48
Per protocol population (n) 46 49 42 45 47 48
Gender
Male 23 (50%) 23 (47%) 20 (48%) 24 (53%) 23 (49%) 24 (50%)
Female 23 (50%) 26 (53%) 22 (52%) 21 (47%) 24 (51%) 24 (50%)
Age (years)
21–30 13 (28%) 19 (39%) 13 (31%) 9 (20%) 15 (32%) 9 (19%)
31–60 30 (65%) 27 (55%) 25 (60%) 31 (69%) 28 (60%) 26 (54%)
>60 3 (7%) 3 (6%) 4 (9%) 5 (11%) 4 (8%) 13 (27%)
Mean ± SD 38 ± 10 38 ± 13 39 ± 13 46 ± 12 43 ± 12 47 ± 16
Ethnicity
Caucasian 44 48 42 45 47 47
Non-caucasian 2 1 0 0 0 1
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ers were taken as non-smoking control values.
For smoking subjects, cigarette ﬁlters were collected for the
24 h periods that corresponded with urine collection and were
used to assess nicotine mouth level exposure (MLE, an estimate
of the amount of nicotine that exits the cigarette ﬁlter and enters
the mouth) with a previously described part-ﬁlter analysis proce-
dure (St Charles et al., 2006). On days 14, 15, 28 and 42, smokers
also completed a questionnaire, adapted for this study, on 11 sen-
sory characteristics of the product, including draw resistance, irri-
tation and acceptability using subjective questions scored on a ﬁve
point scale (McAdam et al., 2011a).
2.5. Statistical analysis
Sample size estimates were based on observed percentage
reductions in smoke toxicants from CC1 to BT1 and TSS1 (given
that the 1 mg RTPs gave the smallest absolute reductions in smoke
toxicants from the control cigarette). Assuming that these reduc-
tions would translate into corresponding BoE reductions, historical
biomarker data were used to estimate the effect size based on the
smallest anticipated change (aromatic amines). Sample size calcu-
lations were carried out using the sample size calculator for a two
sample parity T-test in MINITAB v15 software. We determined that
to achieve power of 80% in the study, a sample size of 50 would be
adequate for all BoE of interest.
Assessments of changes in BoE levels compared values at base-
line with values at mid-point and end of study. BoE data at mid-
point and end of study were compared for each analyte and group
to assess whether any changes noted after two weeks were main-
tained throughout the study.
In all cases, if normality or homogeneity of the variance
assumptions were not respected, a log-transformation or non-
parametric approach was applied. Repeated measures analyses of
variance (ANOVA) or covariance (ANCOVA) were done with SAS
PROC MIXED, on the change from baseline for each BoE, with day-
⁄group interaction as a ﬁxed effect. The repeated measures were
taken into account, with the term subject nested within group as
a random effect, with use of the SAS repeated statement. Signiﬁ-
cance of the interaction was evaluated at a = 0.05. If the day⁄group
interaction was signiﬁcant, the term was maintained in the model
and the group comparison was performed separately for each day.
Otherwise the interaction was removed and the group comparison
was assessed globally. ANCOVA was considered if absolute expo-
sure measurement values could be used. The same model as for
ANOVA was used, but the number of smoked cigarettes was ap-plied as a continuous covariate. ANCOVA was used if the number
of cigarettes per day (CPD) changed over time and a signiﬁcant
relationship was seen between BoE values and CPD that was not
dependent on the ﬁxed effects (day and group). Details of the sta-
tistical analysis plan for this study are available from the authors
on request.
All statistical analyses were performed with SAS DD (UNIX)
Version 9.1 or higher, and edit checks were performed on Open-
VMS platform SAS Version 8.2.
3. Results
Three hundred and one subjects were recruited, of whom 100
smoked 6–7 mg ISO tar yield cigarettes, 151 smoked 1–2 mg ISO
tar yield cigarettes, and 50 were non-smokers. Characteristics of
subjects are shown in Table 2. Of these, 285 (95%) completed the
study. Sixteen did not complete the study because of personal rea-
sons (n = 8), protocol violations (n = 4), pregnancy (n = 2), non-
compliance to the study protocol (n = 1), and an adverse event
(not related to study) (n = 1). A further eight subjects were re-
moved from the analysis because of an incomplete data set for
those subjects. Therefore, the per-protocol population comprised
277 subjects (Table 2).
3.1. Demographic data
The distribution of subjects with respect to age and gender in
the per protocol set was similar across and within study groups
(Table 2). The mean ages for the two 6 mg groups were identical
(38 years). There was some variation between the mean ages for
the three 1 mg groups (39–46 years). However, standard deviation
was similar for all groups. Absolute matching of age was not essen-
tial since 6 mg and 1 mg groups were not compared, and with the
tar categories the primary comparisons are within group rather
than between groups.
3.2. Cigarette consumption and nicotine MLE
Self-reported cigarette consumption was recorded at screening
to meet the inclusion/exclusion criteria, but no measures of con-
sumption or intake were made on subjects own brands prior to
day 1. After day 1, actual cigarettes per day (CPD) were recorded
at multiple time-points during the study and are shown graphi-
cally in Fig. 2. Day to day cigarette consumption was variable
throughout the study for all groups, with no obvious trends, with
the exception of a noticeable uplift in consumption for all groups
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Study Day
Fig. 2. Mean cigarette consumption through Study for all groups.
Table 3
Cigarette consumption and nicotine mouth level exposure at baseline and study end, by study group.
Group LS Mean consumption cigarettes per day LS Mean MLE nicotine (mg/24 h)
Day 14 Day 41 Percentage change (%) p value Day 14 Day 41 Percentage change (%) p value
1 (CC6) 17.6 ± 5.6 19.4 ± 7.1 +10 0.0001 20.3 ± 8.5 23.5 ± 11.2 +16 0.0008
2 (TSS6) 17.1 ± 6.7 17.7 ± 7.7 +3 0.1697 21.4 ± 11.8 23.5 ± 14.1 +10 0.0241
3 (CC1) 18.4 ± 5.1 18.7 ± 5.8 +2 0.5687 12.0 ± 7.2 14.5 ± 8.3 +21 0.0014
4 (TSS1) 17.0 ± 6.5 20.3 ± 7.3 +19 <0.0001 10.6 ± 6.8 18.5 ± 10.4 +74 <0.0001
5 (BT1) 18.0 ± 5.8 17.9 ± 7.9 0.5 0.9172 9.8 ± 6.0 17.0 ± 10.9 +73 <0.0001
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tistically signiﬁcant for groups 1 and 4 (Table 3). This end-of-study
uplift has been noted in previous studies (Shepperd et al., 2009; St
Charles et al., 2006) and could be attributable to the imminent
study end and hence the supply of test cigarettes. Because of this,
day 41 was selected for analysis as the end of study timepoint
rather than day 42. With the exception of this end-of-study effect,
statistical analysis of cigarette consumption suggests that con-
sumption remained reasonably stable throughout the study, and
that subjects were acclimatised to control cigarettes within the ini-
tial 14 day period (Fig. 2).
CPD and nicotine MLE data for all smoking groups for baseline
(day 14) and end of study (day 41) are shown in Table 3. At base-
line, CPD for all groups was 17–18.4, with no signiﬁcant difference
between the groups.
The mean values for MLE nicotine at baseline were similar for
groups 1 and 2 at around 20 mg/24 h and for groups 3, 4 and 5,
at around 11 mg/24 h reﬂecting differences in the nicotine yield
of the two control products. Nicotine MLE increased in all groups
from baseline to end of study (Table 3). The magnitude of this in-
crease was consistent with the changes seen in total nicotine
equivalents (TNeq) for the 6 mg groups (Table 4), but was two to
three times higher than those seen for the 1 mg groups (Table 5).3.3. Biomarkers of exposure
Tables 4–6 detail the biomarker of exposure data for 6 mg
groups, 1 mg groups and non-smokers, respectively. Results for se-
lected BoE are also presented as boxplots in Fig. 3. Tables 7–9 detailthe smoke yield and BoE data expressed as absolute values and%
change between test and control (smoke data) or between baseline
and end of study (BoE) Table 6.3.3.1. 6 mg Groups
In group 1 (CC6) end-of-study levels were higher than at base-
line for all BoE, except those for 3-hydroxyphenanthrene and 4-
hydroxyphenanthrene, which decreased, and for DHBMA, which
did not change (Table 4). Increases were signiﬁcant except those
for NNN, 3-aminobiphenyl, 2-hydroxyphenanthrene and 3-
hydroxyphenanthrene.
By contrast, subjects in group 2 (TSS6) showed reductions in all
biomarkers at end of study compared with baseline except for
TNeq and 4-hydroxyphenanthrene. All reductions were signiﬁcant
except those for 4-aminobiphenyl, 1-hydroxypyrene and 2-
hydroxyphenanthrene, 3-hydroxyphenanthrene and 4-hydroxyph-
enanthrene. TNeq was signiﬁcantly higher at end of study com-
pared to baseline, despite no signiﬁcant increase in CPD. The
greatest reductions were seen for the volatile compounds, which
were reduced by 75%, 45% and 63% for crotonaldehyde, acrolein
and 1,3-butadiene (MHBMA) BoEs respectively. BoEs for the TSNAs
were reduced by between 10% and 26%.3.3.2. 1 mg Groups
In group 3 (CC1), most BoE levels were similar at baseline and
day 41. Statistically signiﬁcant increases were observed for some
BoEs, including acrolein (3-HPMA) and 2-aminonapthalene
(Table 5).
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creased from baseline to end of study, despite there being no case
where there was an increase in toxicant yield when measuring the
smoke chemistry. The volatile species again showed the greatest
statistically signiﬁcant reductions—58%, 40% and 46% for crotonal-
dehyde, acrolein and 1,3-butadiene (MHBMA) biomarkers, respec-
tively. Signiﬁcant increases were seen in concentrations of BoE for
nicotine, NNK, 4-aminobiphenyl, 3-aminobipheny, l, 2-amino
naphthalene and all but one phenanthrene BoE (Table 5). Of the
TSNA BoE, NNK (measured as NNAL) increased signiﬁcantly be-
tween baseline and day 41, while absolute levels of NNN, NAB
and NAT BoE all reduced. A signiﬁcant 19% increase in CPD on
day 41 compared with baseline (Table 3) may account for some
of these increases.
In group 5 (BT1) signiﬁcant reductions in levels were seen for 11
BoE. In particular, reductions in BoE of between 46–86% were seen
for the TSNAs, up to 38% for aromatic amines, 62% for crotonalde-
hyde, 48% for acrolein and 55% for 1,3-butadiene (MHBMA) (Ta-
ble 5). NNAL was not reduced to the same extent as the other
TSNAs and while reductions in NNN, NAB and NAT were in line
with smoke chemistry reductions, NNAL was not. However, NNAL
is a metabolite of NNK with a longer half-life, whilst NNN, NAB and
NAT are smoke constituents with short half-lives. We found a sig-
niﬁcant increase in TNeq of 23%, which was in keeping with the
smoke nicotine yields of CC1 and BT1 (Table 1). There were also
signiﬁcant increases in 2-hydroxyﬂuorene, 1-hydroxynaphthalene
and three of the hydroxyphenanthrenes.
3.4. Non-smoker Group
The difference in BoE levels between the smoker and non-smo-
ker groups depended on the BoE. Detectable levels of TNeq and
TSNA BoEs were found in the non-smoker group, suggesting some
previous level of exposure to environmental tobacco smoke. The
mean level of TNeq was around 0.3% of that of the smoker group.
Two BoEs were measured for 1,3-butadiene. The mean level of
MHBMA for group 1 was 4501 ng/24 h, compared to the corre-
sponding level in non-smoker (group 6) of 117 ng/24 h, whereas
the level of DHBMA was 484 lg/24 h in group 1 compared to
332 lg/24 h in group 6.
For groups 2, 4 and 5, in no case did the BoE level at day 41 reach
the level found in group 6, though for BoEs where there were sub-
stantial reductions in smoke yields, such as crotonaldehyde, BoEs
in these groups became much closer to the mean group 6 level.
3.5. Mid-point data
Full BoE data including data for the mid-point of the study (day
28) are available in additional ﬁles 1–4.
In general, levels of BoE did not differ signiﬁcantly between
days 28 and 41 but there were some exceptions (see additional Ta-
bles 10, 11 and additional Figs. 6, 7). TNeq for the 1 mg RTP groups
increased signiﬁcantly and systematically from day 14 to day 28 to
day 41 and a similar pattern was seen for nicotine MLE values. Re-
sults suggest that the elimination half-lives of most of BoE were
short, i.e. reductions were achieved within the ﬁrst 2 weeks follow-
ing the switch. Since these reductions were generally maintained
for the remainder of the study (two timepoints), it suggests that
subjects complied with the protocol, and that a shorter period of
study could have fulﬁlled the primary objectives for most BoEs.
3.6. Smoke chemistry vs biomarker changes
Included in Tables 7–9 are the percent changes in toxicant
yields as measured on smoking machines (Test vs Control product)
displayed alongside the percent changes in biomarkers.
Table 6
LS Means, SD and ranges for biomarkers of exposure in non-smokers (group 6).
Biomarker* Group 6 (NS)
Day 56
TNeq (mg/24 h) 0.04 ± 0.04 (0.02–0.26)
NNAL(ng/24 h) 22 ± 61 (1–411)
NNN (ng/24 h) 0.9 ± 0.9 (0.3–5.3)
NAB (ng/24 h) 1.5 ± 3.2 (0.4–22.8)
NAT (ng/24 h) 3.6 ± 16.7 (0.3–115.4)
4-Aminobiphenyl (ng/24 h) 2.0 ± 1.0 (0.5–4.9)
3-Aminobiphenyl (ng/24 h) 0.5 ± 0.3 (0.2–2.3)
o-Toluidine (ng/24 h) 53.9 ± 29.6 (19.3–137.2)
HMPMA (lg/24 h) 189 ± 80 (59–419)
2-Amino naphthalene (ng/24 h) 1.6 ± 0.87 (0.4–3.6)
2-Hydroxy ﬂuorene (ng/24 h) 398 ± 303 (79–1773)
1-Hydroxy pyrene (ng/24 h) 105 ± 65 (37–336)
1-Hydroxy naphthalene (ng/24 h) 545 ± 671 (119–3700)
2-Hydroxy naphthalene (ng/24 h) 3726 ± 4728 (590–26,662)
3-HPMA (lg/24 h) 251 ± 125 (54–5730)
MHBMA (ng/24 h) 117 ± 78 (40–447)
DHBMA (mg/24 h) 332 ± 107 (132–602)
2-Hydroxy phenanthrene (ng/24 h) 96 ± (19–658)
3-Hydroxy phenanthrene (ng/24 h) 104 ± 54 (36–262)
4-Hydroxy phenanthrene (ng/24 h) 37.3 ± 37 (6–208)
1 + 9-Hydroxy phenanthrene (ng/24 h) 282 ± 185 (70–1131)
* TNeq = total nicotine equivalents; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N-nitroso-
nornicotine, NAB = N-nitrosoanabasine; NAT = N-nitrosoanatabine; HMPMA =
3-hydroxy-1-methylpropylmercapturic acid; 3-HPMA = 3-hydroxypropylmercapturic
acid; DHBMA = 1,2-dihydroxybutyl mercapturic acid; MHBMA = monohydroxyb-
utenyl-mercapturic acids.
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For groups 1 and 2, CC6 and TSS6, the percentage changes in va-
pour phase toxicant yield corresponded reasonably well with the
reductions in BoE levels. For example a 55% reduction in smoke
yield of acrolein corresponded to a 44% reduction in the BoE for
acrolein, 3-HPMA (Table 7). In the case of 1,3-butadiene the reduc-
tions for the BoE MHBMA were greater than the smoke yield
reductions.
However, for the particulate phase constituents BoE reductions
are typically less, often considerably less, than the smoke yield
reductions. For example a reduction in smoke yield of 50% for
NNN compared to a reduction of 28% in the NNN BoE.
3.6.2. 1 mg Groups
There were reductions in all toxicant yields for the TSS1 RTP vs
the CC1 control although the degree of reduction varied by toxicant
(Table 8). The BoE data for group 4 (TSS1) showed varied responses
including a reasonable number of increases so comparison between
changes in yield and BoE were often not in agreement. For example,
there was a reduction in NNK yields comparing TSS1 with CC1, but
an increase in NNAL for the group switched from CC1 to TSS1.
In group 5 (BT1), there were generally similar reductions in
smoke yields and BoE. Some of these reductions were substantial,
and included decreases of greater than 80%.
Reductions in smoke yields and biomarkers for three of the four
TSNAs were in agreement: Smoke yield reductions for NNN, NAB
and NAT were between 85% and 96%, and reductions in BoE for
these toxicants ranged between 81% and 87%. However the NNK
reductions in smoke yield of 83% did not correspond well with
BoE reductions, which on average were 49% (Table 9). Again, this
difference is most likely due to the fact that NNAL is a metabolite
with a long half-life, while the other TSNAs are un-metabolised
with shorter half-lives.
3.6.3. General observations
For all RTPs, changes in the levels of NNAL and naphthalene did
not compare well with changes in the corresponding smoke yields.However NNN, NAB, NAT, crotonaldehyde, acrolein showed clear
and stable trends, with signiﬁcant reductions across all RTPs with
respect to both smoke yields and BoEs.3.7. Variation in individual participant changes
Fig. 4 provides a descriptive example of individual subject data
for one BoE: NAT, and illustrates the large range of individual re-
sponses seen across the study population. It was common within
a group to see some subjects increase BoE levels even if the group
as a whole showed a signiﬁcant decrease, as exempliﬁed by TSS1
results in Fig. 4. The BT1 results in this example are a rare case
where all individuals reduced their BoE level for NAT. Consider-
ation of the individual participant data from this study will be
the subject of a separate manuscript.3.8. Sensory data
In general, subjects reported equivalence or lower acceptability
for RTPs in most of the sensory categories (Fig. 5). On occasions
there was substantially lower acceptability, however overall
acceptability of the prototypes seemed to improve over the course
of the 4 weeks that the participants were smoking them.4. Discussion
The primary objective of the study was to estimate and compare
cigarette smoke exposure in healthy adult smokers using both BoE
and ﬁlter analysis, and to quantify any changes in these exposure
estimates following a switch from commercial-style to novel ciga-
rettes. 92% of enrolled subjects successfully completed the study to
protocol, providing BoE and ﬁlter analysis results for statistical
analysis.
This proof-of-concept clinical study demonstrates that signiﬁ-
cant reductions in tobacco smoke toxicant yields observed in ma-
chine smoking of RTPs can translate to reductions in BoE levels
in smokers. However, yield reductions did not always lead to BoE
reductions, and varied widely between individuals.
All three RTPs were associated with reductions in yields of mul-
tiple smoke toxicants compared to their control cigarettes and, for
some of these, reductions were substantial. BoE levels for the vol-
atile smoke toxicants crotonaldehyde, acrolein and 1,3-butadiene
(MHBMA) were substantially reduced in smokers of all three RTP
cigarettes as predicted by smoke toxicant yields. Levels of three
of the four TSNAs (NNN, NAB, NAT) also showed signiﬁcant reduc-
tions, largely in keeping with the smoke toxicant yields. None of
the test products, despite having substantially reduced levels in
some smoke toxicants, reduced BoE levels to those found in non-
smokers, though in some cases reductions led to levels that came
close to non-smoker levels. The control cigarettes were associated
with urinary BoE levels that were in keeping with published data
for European smokers (Lindner et al., 2011). For groups of individ-
uals who switched to the RTPs, toxicant biomarkers were generally
correlated with nicotine biomarkers indicating that uptake of tox-
icant was determined by concentration in smoke and inhaled
amount of smoke. This correlation is not shown here but will be
explored in a subsequent paper (in preparation) that considers
the correlation between toxicant tield as measured under different
machine smoking regimes and human exposure as determined
using BoE.
Although reductions were seen across all smoke toxicants in
RTPs, compared with their controls, the BoE data showed increases
in exposure for several of these toxicants. In the case of TSS1, group
4, there was a distinct increase in consumption per day at day 41,
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to be a key inﬂuencer on toxicant exposure.
In this study the BoE and ﬁlter analysis samples were acquired
during clinical conﬁnement. Clinical conﬁnement may help with
compliance to protocol, but smoking in this environment maynot reﬂect natural behaviour even though subjects were free to
smoke ad libitum in an effort to minimise any potential changes
in smoking behaviour. We found increased cigarette consumption
at the end of the study, which could be due to a variety of factors
including the imminent end of the supply of free cigarettes. Exten-
Table 7
Smoke yields and biomarkers of exposure of 6 mg cigarette groups (CC6 vs TSS6).
Smoke constituent Smoke yields Biomarker Biomarker data
CC6 TSS6 Amount: Group 4 (TSS6)
Yield Yield D (%) Day 14 Day 41 D (%)*
Nicotine (mg/cig) 1.6 1.4 13 Tneq (mg/24 h) 11.7 12.9 10
NNK (ng/cig) 80 44.5 44 NNAL (ng/24 h) 315 282 10
NNN (ng/cig) 146.9 72.8 50 NNN (ng/24 h) 14.8 11.5 22
NAB (ng/cig) 12.1 7.6 37 NAB (ng/24 h) 35.3 26.2 26
NAT (ng/cig) 117.6 69.5 41 NAT (ng/24 h) 187 143 24
4-Aminobiphenyl (ng/cig) 3.1 2.7 13 4-Aminobiphenyl (ng/24 h) 15.7 14.7 6
3-Aminobiphenyl (ng/cig) 4.1 3.3 20 3-Aminobiphenyl (ng/24 h) 6.8 6.1 10
o-Toluidine (ng/cig) 88.1 76.2 14 o-Toluidine (ng/24 h) 143 131 8
Crotonaldehyde (lg/cig) 45.2 7 85 HMPMA (lg/24 h) 1215 308 75
2-Aminonaphthalene (ng/cig) 14.6 14.8 1 2-Amino naphthalene (ng/24 h) 23.7 21.1 11
Fluorene (ng/cig) 315.7 240.9 24 2-Hydroxy ﬂuorene (ng/24 h) 2587 2232 14
Pyrene (ng/cig) 108.1 80.3 26 1-Hydroxy pyrene (ng/24 h) 283 267 6
Naphthalene (ng/cig) 2952.3 565.6 81 1-Hydroxy naphthalene (ng/24 h) 7103 6065 15
2-Hydroxy naphthalene (ng/24 h) 13904 12323 11
Acrolein (mg/cig) 139.4 62.3 55 3-HPMA (lg/24 h) 1365 751 45
MHBMA (ng/24 h 4028 1487 63
1,3-Butadiene (mg/cig) 63.6 36.8 42 DHBMA mg/24 h) 440 407 8
2-Hydroxy phenanthrene (ng/24 h) 113 108 4
Phenanthrene (ng/cig) 739.8 589.7 20 3-Hydroxy phenanthrene (ng/24 h) 217 207 5
4-Hydroxy phenanthrene (ng/24 h) 55 68 24
1+9-hydroxy phenanthrene (ng/24 h) 578 526 9
* D (%) data are the means of the per subject percentage changes.
Table 8
Smoke yields and biomarkers of exposure of 1 mg cigarette groups, part 1 (CC1 vs TSS1).
Smoke constituent Smoke yields Biomarker Biomarker data
CC1 TSS1 Amount: Group 4 (TSS1)
Yield Yield D (%) Day 14 Day 41 D (%)*
Nicotine (mg/cig) 1.3 1.2 8 Tneq (mg/24 h) 7.3 9.8 34
NNK (ng/cig) 57.9 48.2 17 NNAL (ng/24 h) 207 271 31
NNN (ng/cig) 245.2 76 69 NNN (ng/24 h) 12.2 8.3 32
NAB (ng/cig) 13.6 6.6 51 NAB (ng/24 h) 23.5 20.5 13
NAT (ng/cig) 124.5 70.3 44 NAT (ng/24 h) 144 99.0 31
4-Aminobiphenyl (ng/cig) 2.8 2.5 11 4-Aminobiphenyl (ng/24 h) 10.1 12.6 25
3-Aminobiphenyl (ng/cig) 3.5 3 14 3-Aminobiphenyl (ng/24 h) 4.2 5.4 29
o-Toluidine (ng/cig) 68.1 60.1 12 o-Toluidine (ng/24 h) 122 111 9
Crotonaldehyde 41.6 6 86 HMPMA (lg/24 h) 680 288 58
2-Aminonaphthalene (ng/cig) 13.1 11.5 12 2-Amino naphthalene (ng/24 h) 15.0 19.6 30
Fluorene (ng/cig) 230.5 148.3 36 2-Hydroxy ﬂuorene (ng/24 h) 1627 1751 8
Pyrene (ng/cig) 70.4 64.6 8 1-Hydroxy pyrene (ng/24 h) 175 190 9
Naphthalene (ng/cig) 2182.5 643.8 71 1-Hydroxy naphthalene (ng/24 h) 4201 4213 <1
2-Hydroxy naphthalene (ng/24 h) 8377 8234 2
Acrolein (lg/cig) 130.5 52.5 60 3-HPMA (lg/24 h) 1016 619 39
1,3-Butadiene (lg/cig) 39.6 27.2 31 MHBMA (ng/24 h) 3109 1684 46
DHBMA (lg/24 h) 448 413 8
Phenanthrene (ng/cig) 524.4 191.4 64 2-Hydroxy phenanthrene (ng/24 h) 86 124 44
3-Hydroxy phenanthrene (ng/24 h) 150 172 15
4-Hydroxy phenanthrene (ng/24 h) 43 51 19
1 + 9-Hydroxy phenanthrene (ng/24 h) 347 524 51
* D (%) data are the means of the per subject percentage changes.
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data analysis, might be useful to avoid increased consumption
affecting results.
BoE data will not only reﬂect behaviour during conﬁnement but,
depending on the half-life of the biomarker, may also reﬂect behav-
iour in the days immediately before clinical conﬁnement. Most of
the biomarkers have a short half-life however NNK is an exception.
It has been reported as biphasicwith aﬁrst-phase elimination (t1/2a)
occurring between 14 h and 3.3–4.0 days and second-phase elimi-
nation (t1/2b) between 10–18 days and 39–45 days (Goniewicz
et al., 2009; Hecht et al., 1999). This may explain the discrepancies
in our data for NNK. Owing to the timescale of this study, measure-ment of NNAL is unlikely to have fully reﬂected the exposure toNNK
after switching. The behaviours of NNAL and the two BoE for naph-
thalene were the least consistent with smoke yield changes. Differ-
ences in the NNK smoke yields consistently overestimated the total
reductions in NNAL achievable with RTPs, by around 50%, although
for TSS1 the reduction in NNK yield was associated with an increase
in NNAL challenging the notion that this is simply a half-life effect.
The ﬁnding was pronounced with the two naphthalene biomarkers,
wherenaphthalene smokeyieldswere70–80% lowerwithRTPs than
with control cigarettes, butunder real-life conditions thedifferences
for 1-hydroxynaphthalene and 2-hydroxynaphthalene were less
than 30%. A similar explanation is unlikely for 1-hydroxynaphthalene
Table 9
Smoke yields and biomarkers of exposure of 1 mg cigarette groups, part 2 (CC1 vs BT1).
Smoke constituent Smoke yields Biomarker Biomarker data
CC1 BT1 Amount: Group 5 (BT1)
Yield Yield D (%) Day 14 Day 41 D (%)*
Nicotine (mg/cig) 1.3 1.5 15 Tneq (mg/24 h) 8.0 9.8 23
NNK (ng/cig) 57.9 10.1 83 NNAL (ng/24 h) 238 128 46
NNN (ng/cig) 245.2 10.2 96 NNN (ng/24 h) 15.8 2.2 86
NAB (ng/cig) 13.6 1.4 90 NAB (ng/24 h) 30.1 5.9 80
NAT (ng/cig) 124.5 19.1 85 NAT (ng/24 h) 186 28.5 85
4-Aminobiphenyl (ng/cig) 2.8 1.2 57 4-Aaminobiphenyl (ng/24 h) 11.1 6.9 38
3-Aminobiphenyl (ng/cig) 3.5 1.8 49 3-Aminobiphenyl (ng/24 h) 4.3 2.7 37
o-Toluidine (ng/cig) 68.1 50.6 26 o-Toluidine (ng/24 h) 130 124 5
Crotonaldehyde 41.6 10.9 74 HMPMA (lg/24 h) 741 275 62
2-Aminonaphthalene (ng/cig) 13.1 7.4 44 2-Amino naphthalene (ng/24 h) 16.3 13.8 15
Fluorene (ng/cig) 230.5 247.3 7 2-Hydroxy ﬂuorene (ng/24 h) 1794 2134 19
Pyrene (ng/cig) 70.4 75.3 7 1-Hydroxy pyrene (ng/24 h) 190 197 4
Naphthalene (ng/cig) 2182.5 484.9 78 1-Hydroxy naphthalene (ng/24 h) 4847 5744 16
2-hydroxy naphthalene (ng/24 h) 9184 10,415 13
Acrolein (lg/cig) 130.5 75 43 3-HPMA (lg/24 h) 1137 596 48
1,3-Butadiene (lg/cig) 39.6 53.4 35 MHBMA (ng/24 h) 4146 1882 55
DHBMA (lg/24 h) 463 421 9
Phenanthrene (ng/cig) 524.4 541.5 3 2-Hydroxy phenanthrene (ng/24 h) 100 111 11
3-Hydroxy phenanthrene (ng/24 h) 165 181 10
4-Hydroxy phenanthrene (ng/24 h) 37 63 70
1 + 9-Hydroxy phenanthrene (ng/24 h) 360 429 19
* D (%) data are the means of the per subject percentage changes.
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has been reported in workers exposed to hot asphalt (Sobus et al.,
2009).
Levels of DHBMA and all BoE for phenanthrene were similar in
the smoker and non-smoker groups. This observation has been re-
ported previously (U.S. Department of Health and Human Services,
2010). The high levels in non-smokers were presumably related to
environmental and/or dietary sources of exposure, and may limit
the resolving power of these biomarkers as measures of smoke tox-
icant exposure reduction. As none of the biomarkers show good
selectivity for phenanthrene, it is questionable whether any should
be included in future studies of this kind. For 1,3-butadiene,
MHBMA appeared to have much greater selectively than DHBMA
and, in keeping with previously published opinion (U.S. Depart-
ment of Health and Human Services, 2010) it must be concluded
that DHBMA is not a viable biomarker for 1,3-butadiene.
The ﬁlter analysis MLE data for the 6 mg control cigarettes and
RTPs were in line with the smoke yields and TNeqs whilst, in con-
trast the 1 mg controls and RTPs were not. In principle the ﬁlter
analysis methodology should not be inﬂuenced by the ﬁlter con-
structions of the 1 mg RTPs. If smokers of the 1 mg RTP puffed at
a ﬂow rate substantially different to that used during method cal-
ibration, then estimates of MLE can be less accurate. However, lim-
ited pufﬁng topography data collected during this study (data not
show) indicated that smokers smoked the RTP cigarettes in manner
that was broadly similar to the control cigarettes. Even so, applica-
tion of the ﬁlter analysis method can become more challenging
with highly-ventilated 1 mg ISO tar yield products, and the appli-
cability of this assay to very novel ﬁlter designs warrants further
study.
Despite the general increase in nicotine measures for all the
1 mg groups, the per cigarette data (0.63–0.89 mg/cig nicotine
MLE and 0.43–0.52 mg/cig TNeq (per cig data not shown)) re-
mained in keeping with previously published MLE and TNeq data
for a commercial 1 mg cigarette in Germany (0.82 and 0.40 mg/
cig, respectively Shepperd et al., 2009).
Variation between individuals in this study was large and pre-
sumably reﬂects both individual smoking behaviour and inter-
individual variation in metabolism. These variations mean thatwhile group mean BoE may reduce, not all subjects in the group
actually experiences decreases in BoE levels. There were no health
end-points in this study, therefore the likely impact on long term
health risks which might be associated with reducing some but
not all tobacco smoke toxicants cannot be assessed. Longer term
studies of RTPs that include markers of biological relevance should
be considered.
The US Food and Drug Administration (FDA) have been develop-
ing guidelines for applications related to modiﬁed risk tobacco
products (MRTPs) either related to reduced exposure to toxicants
or reduced health risks. As part of the development of these guide-
lines, the FDA commissioned the Institute of Medicine to produce a
report on scientiﬁc standards in studies of MRTPs, informed by a
series of studies and reviews by Hatsukami and others, that set
out the methodological challenges of assessing MRTPs (Hatsukami
et al., 2006, 2009). The FDA has recently provided draft guidance on
both what are harmful and potentially harmful constituents in to-
bacco and tobacco smoke (FDA Guidance for Industry, 2012a), and
on what studies are needed to assess modiﬁed risk tobacco prod-
ucts (FDA Guidance for Industry, 2012b). The measurement of
BoE of tobacco smoke toxicants could be important to regulatory
approaches related both to the assessment of potential MRTPs
and to approaches seeking to reduce exposures to tobacco smoke
toxicants through the setting of product standards.
This study, although demonstrating reductions in the BoE for
a number of smoke toxicants is clearly insufﬁcient to meet the
level of scientiﬁc evidence required to allow the products to be
assessed as an MRTP, under IoM, FDA and our own proposed
framework of scientiﬁc assessment for such products (Proctor
and Ward, 2011). It does illustrate that more work is still needed
on the methodology employed in clinical studies designed to as-
sess tobacco products with reduced toxicant levels. Additional
BoEs should be developed to represent important toxicants,
and the performance of some existing BoEs could be improved
by measuring additional metabolites, or at least developing a
greater understanding of metabolic pathways for some toxicants.
Since the suite of nicotine plus ﬁve metabolites are known to
amount to approximately 80% of nicotine intake (Benowitz
et al., 1994) it is conventional to sum as TNeq (Total nicotine
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Fig. 4. Individual subject results for NAT BoE per day (top plot) and per cigarette (bottom plot).
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would therefore be an advantage.
A study design that includes occasional clinical conﬁnement
seems to inﬂuence daily cigarette consumption, especially as the
study comes to a close, and daily consumption can have an impor-
tant impact on BoE levels, suggesting designs that run longer than
needed for the clinical assessment might be necessary.
Most importantly, although this study shows that reductions in
smokers’ exposure to toxicants as measured by BoE is possible by
reducing smoke toxicant yields, more research is needed to assess
whether such reductions will have an effect on health risks. Such
research should, as a ﬁrst step, include biomarkers of biological ef-
fect, that being endogenous compounds released by the body in re-
sponse to stress such as toxicant exposure. These might include F2-
isoprostane (for oxidative stress) and sICAM-1 and white blood cell
count for cardiovascular disease.5. Conclusions
The primary objective of the study was to estimate and compare
cigarette smoke exposure in healthy adult smokers by assessment
of BoE and mouth level exposure (MLE) to tar and nicotine (as mea-
sured by ﬁlter analysis), and to quantify any changes in exposure
after switching from control cigarettes to RTPs.
The study found that large reductions in smoke toxicant yields
can reduce mean BoE levels in groups of smokers (as seen in the
BoE levels of vapour phase toxicants), but that smoking behaviour
remains an important determinant of toxicant exposure and that
cigarettes that demonstrate reductions in toxicant yields as mea-
sured by smoking machines can still result in increases in BoE lev-
els in groups of smokers. Generally, where the reductions in
toxicant levels were very large, as was the case for acrolein and
crotonaldehyde, there were corresponding large reductions in
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was more likely to be seen for many of the particulate phase toxi-
cants, mean BoE may still increase following a switch from a con-
ventional cigarette to a RTP. Increases in daily cigarette
consumption or other more-intensive smoking behaviours can
undermine the reductions seen in toxicant yields. This study con-
ﬁrms that individual smoking behaviours vary widely, and this,
perhaps in addition to other factors such as variations in metabo-
lism, results in wide ranges in BoE levels across the smoker
population.Not all BoEs behaved the same. This was particularly true across
the range of tobacco-speciﬁc nitrosamine BoEs, where NNAL gave
quite different results from the other TSNA BoEs. This suggests that
in such studies a range of biomarkers should be measured.
MLE levels corresponded with BoE measures of nicotine expo-
sure for the higher ISO tar yield products (RTP and control) but
not for the lower ISO tar yield RTPs, and more research is needed
into the methodology used in MLE for very novel products.
The reductions in BoE for smoke toxicants demonstrated in this
study show that it is possible to reduce exposure to some tobacco
162 C.J. Shepperd et al. / Regulatory Toxicology and Pharmacology 66 (2013) 147–162smoke toxicants, as measured by smoke chemistry, by switching
smokers from conventional cigarettes to RTPs. However, the study
found considerable variability in both absolute BoE levels and per-
centage reductions, in some cases BoE increased and in no case
were the reductions in toxicant exposure so large as to reduce
exposures to non-smoker levels. Further evaluation should be
undertaken on the impact of cigarettes with substantially reduced
levels of tobacco smoke toxicants on longer-term behaviours, and
such studies should include end points that assess the possible ef-
fects of reductions on health.
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